Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)

Trial Profile

Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Retinal pigment epithelial cell replacement therapy-Cell Cure Neurosciences (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Cell Cure Neurosciences
  • Most Recent Events

    • 28 Aug 2017 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
    • 28 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 25 Jul 2017 According to a BioTime media release, for cohort 3 optimization of the implant for cell concentration and volume is ongoing. The company expects to start enrolling patients in cohort 3 in the coming weeks and complete during the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top